ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

计划入组 53 人 · 首次发布于 2025 年 1 月 15 日

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

计划入组 492 人 · 首次发布于 2019 年 1 月 14 日

PETACC-8 miR-31-3p and miR-31-5p Ancillary Study

计划入组 1,808 人 · 首次发布于 2017 年 12 月 5 日

VAX-31

SCC-31

XHL-31

Orient Pharma Co., Ltd.

Taiwan

Orient Europharma Co., Ltd.

Taiwan

ORIENT EUROPHARMA PTE LTD

Singapore

Benmelstobart Plus Anlotinib Shows Promise in EGFR-Mutated NSCLC After TKI Failure

Vaxcyte's VAX-31 Demonstrates Positive Phase 1/2 Results, Advancing to Phase 3 for Pneumococcal Disease

George Medicines Expands Global Reach of Triple-Combination Hypertension Drug GMRx2 Through Strategic Licensing Deals